The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- fMRI during learning task
研究概览
简要总结
The hippocampus is particularly laden with n-methyl-d-aspartate (NMDA) receptors, and is at the same time one of the most important sites in declarative memory. The rationale of this study is that the NMDA partial agonist D-Cycloserine will promote learning compared to a placebo. On the other hand, the NMDA receptor antagonist Memantine might lead to reduced memory. We believe that the influence of NMDA receptors on memory can be determined via acute co-activation of the NMDA receptors with Cycloserine® (King Pharmaceuticals Ltd, active ingredient: DCycloserin, dose: 250 mg) and Memantine (Axura®, Merz, active ingredient: Memantine, dose: 20 mg)on both a behavioral and functional (fMRI) level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •German native language or native language level
- •Able to give written informed consent
- •right-handed
排除标准
- •inability to give written informed consent, underaged minors, contractually incapable persons, persons in legal custody
- •any psychiatric, neurological or internal illness
- •hematoporphyria (enzyme sickness)
- •intake of medication (except oral contraceptives)
- •simultaneous participation in other clinical studies
- •hypersensitivity to Memantine or other anti-dementia substances, or to D-Cycloserine
- •alcohol abuse
- •depression
- •serious anxiety or psychosis
- •serious kidney insufficiency
- •intake of Ethionamide or Isoniazide
- •pregnancy or women who are nursing
- •liver or kidney problems
- •intake of NMDA-antagonists, such as Amantadine, Ketamine, or Dextromethorphan
- •vegetarians
- •stomach ulcer, if treated with medication
- •renal tubular acidosis
- •urinary infections (with proteus bacteria)
- •recent heart attack, heart failure, or uncontrolled high blood pressure
- •intake of L-Dopa, dopaminergic agonists, and anticholinergics
- •intake of barbiturates, spasmolytics, Phenytoin, Amantadine, oral coagulators, warfarin, HCT (Hydrochlorothiazide)
- •heart or cranial operations
- •pacemaker, medication pump (such as insulin pump), hearing aid, removable prosthodontics
- •metal in or on body (such as acupuncture needles, artificial limbs, stents, metal splints, clips, implanted electrodes, tattoos, or piercings)
- •claustrophobia
研究组 & 干预措施
Sugar pill, behavioral glutamic acid
Placebo condition for D-Cycloserine
干预措施: Sugar pill (Drug)
Sugar pill, fMRI, glutamic acid
Placebo condition for D-Cycloserine, fMRI
干预措施: Sugar pill (Drug)
Sugar pill, memantine, behavioral
Placebo condition Memantine, behavioral
干预措施: Sugar pill (Drug)
Sugar pill, memantine, fMRI
Placebo condition Memantine, fMRI
干预措施: Sugar pill (Drug)
D-Cycloserine behavioral
干预措施: Glutamic Acid (Drug)
D-Cycloserine, fMRI
干预措施: Glutamic Acid (Drug)
Memantine, behavioral
干预措施: Memantine (Drug)
Memantine, fMRI
干预措施: Memantine (Drug)
结局指标
主要结局
fMRI during learning task
时间窗: once at drug administration
次要结局
未报告次要终点
研究者
Rene Hurlemann
MD
University Hospital, Bonn